logo
Twitter
Discord
Email
logo
AMN Healthcare Services, Inc.

AMN Healthcare Services, Inc.

NYSE•AMN
CEO: Ms. Caroline Sullivan Grace
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 2001-11-13
AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.
Contact Information
8840 Cypress Waters Boulevard, Suite 300, Dallas, TX, 75019, United States
866-871-8519
www.amnhealthcare.com
Market Cap
$750.39M
P/E (TTM)
-2.5
17.9
Dividend Yield
--
52W High
$42.41
52W Low
$14.87
52W Range
17%
5.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q2 2025 Data

Revenue

$658.18M-11.14%
4-Quarter Trend

EPS

-$3.02-802.33%
4-Quarter Trend

FCF

$68.75M-4.85%
4-Quarter Trend

2025 Q2 Earnings Highlights

Key Highlights

Revenue Declined 14% Six months revenue totaled $1.35B USD, declining 14% from prior year period, driven by Nurse Solutions segment.
Major Goodwill Impairment Recorded $109.5M goodwill impairment loss in Physician and Leadership Solutions segment due to lower volume forecasts.
Stable Operating Cash Net cash provided by operating activities was $171.2M USD for the six months ended June 30, 2025.
Asset Sale Completed Completed sale of Smart Square workforce optimization offering on July 1, 2025, receiving $65.3M cash consideration.

Risk Factors

Significant Net Loss Six months net loss reached $(117.3M) USD, reversing prior year net income of $33.6M USD.
Nurse Staffing Volume Nurse segment revenue fell 17% for six months due to lower traveler volume and bill rate compression.
Gross Margin Compression Consolidated gross margin compressed to 29.3% (6M) from 31.2% (6M) due to increased provider pay packages.
Asset Impairment Recognized Recognized $18.3M impairment loss on customer relationships intangible assets within Nurse and Allied Solutions segment.

Outlook

Sufficient Liquidity Expected Cash flow and available borrowings expected sufficient to fund operations and capital needs for the next 12 months.
MSP Revenue Remains Key Managed Service Program revenue comprised 46% of total consolidated revenue for the six months ended June 30, 2025.
Assessing Tax Legislation Currently evaluating the impact of the One Big Beautiful Bill Act enacted July 4, 2025 on future tax provisions.
Credit Facility Available Maintained $659.6M available credit under Senior Credit Facility as of June 30, 2025, with $70.0M drawn.

Peer Comparison

Revenue (TTM)

AMN Healthcare Services, Inc.AMN
$2.77B
-14.3%
InnovAge Holding Corp.INNV
$853.70M
+11.8%
Myriad Genetics, Inc.MYGN
$832.90M
+3.8%

Gross Margin (Latest Quarter)

InnovAge Holding Corp.INNV
213.4%
+195.0 pp
Vir Biotechnology, Inc.VIR
99.1%
+139.3 pp
Ginkgo Bioworks Holdings, Inc.DNA
81.0%
+5.4 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PNTG$865.78M32.29.9%41.7%
MRVI$798.94M-2.2-63.0%41.4%
VIR$777.93M-1.4-50.2%7.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.4%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $658.18M-11.1%
    |
    EPS: $-3.02-802.3%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 9, 2025|
    Revenue: $689.53M-16.0%
    |
    EPS: $-0.03-106.3%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 21, 2025|
    Revenue: $2.98B-21.3%
    |
    EPS: $-3.85-171.6%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 8, 2024|
    Revenue: $687.51M-19.4%
    |
    EPS: $0.18-87.1%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 9, 2024|
    Revenue: $740.69M-25.3%
    |
    EPS: $0.43-72.4%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 10, 2024|
    Revenue: $820.88M-27.1%
    |
    EPS: $0.45-77.8%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 22, 2024|
    Revenue: $3.79B-27.7%
    |
    EPS: $5.38-46.0%
    Miss

  • Form 10-Q - Q3 2023

    Period End: Sep 30, 2023|Filed: Nov 6, 2023|
    Revenue: $853.46M-25.0%
    |
    EPS: $1.39-34.1%
    Miss